GET DAILY SIGNALSRadNet (RDNT) Delivers Q3 Adjusted EPS Beat Despite Narrow Revenue Miss
Key Takeaways
- RadNet reported adjusted earnings per share (EPS) of $0.30 for the third quarter of 2026, beating the consensus estimate of $0.22 by $0.08.
- Total revenue rose roughly 22% year over year to $638.26 million, slightly below the $639.67 million consensus estimate.
- On a generally accepted accounting principles (GAAP) basis, net income was $4.15 million, or $0.05 per diluted share, compared with $5.42 million, or $0.07 per share, a year earlier.
- The company's profitability beat helped support investor confidence even as the top line came in just shy of Wall Street's forecast.
- Get more details on RadNet's Major News, Today's Price Move, Price Targets, and Forecast on dedicated Tickeron pages.
- Explore Trending AI Robots to discover AI-driven trading strategies built for changing market conditions.
Why These Results Stand Out
RadNet, Inc. (RDNT) operates one of the largest networks of outpatient diagnostic imaging centers in the United States while expanding its DeepHealth digital health and artificial intelligence platform. Quarterly results from the company often highlight broader shifts in healthcare demand, reimbursement trends, and the pace of AI adoption in radiology. The firm has posted consistent double-digit revenue growth fueled by higher same-center volumes, a shift toward advanced imaging procedures, and acquisitions. Attention now centers on how quickly the Digital Health segment can scale recurring AI and informatics revenue and translate that expansion into stronger profits.
Quarterly Numbers in Detail
For the third quarter ended September 30, 2026, RadNet (RDNT) posted revenue of $638.26 million, an increase of about 22.1% from $522.87 million a year earlier. The figure landed just below the consensus target of $639.67 million. Adjusted EPS reached $0.30, surpassing the analyst estimate of $0.22 by $0.08. GAAP net income from continuing operations came in at $4.15 million, or $0.05 per diluted share, versus $5.42 million, or $0.07 per share, in the prior-year quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The gap between adjusted and GAAP results stems mainly from acquisition costs and other non-cash items that management removes when assessing core performance. The stronger adjusted profit, alongside revenue that fell only narrowly short of expectations, showed that profitability momentum exceeded revenue growth relative to forecasts.
How the Market Responded
Shares of RadNet (RDNT) climbed roughly 2.8% after the release, according to earnings coverage. Investors appeared to emphasize the adjusted earnings outperformance and ongoing revenue expansion more than the modest revenue shortfall. Pre-report sentiment had been supported by the pattern of double-digit top-line gains and accelerating digital health momentum, although reimbursement policy shifts remain a sector-wide concern.
What to Watch Going Forward
Attention now turns to whether RadNet (RDNT) can maintain revenue momentum while lifting adjusted profitability. Management has already increased full-year 2026 guidance for the Imaging Center segment, with targets of roughly $2.37 billion to $2.42 billion in revenue, adjusted EBITDA between $345 million and $358 million, and free cash flow of $115 million to $125 million.
The Digital Health segment continues to draw focus. Rapid growth in annual recurring revenue from DeepHealth AI and informatics products remains a key metric, and investors will track progress toward year-end targets. Reimbursement policy is another variable. The Centers for Medicare & Medicaid Services issued its final Medicare physician fee schedule rule in early November, which includes a reduction to the conversion factor. The precise effect on RadNet will depend on its payer and procedure mix, but such changes represent an important industry factor.
Additional signals to monitor include acquisition integration progress, same-center volume trends, and the rate of AI adoption across the imaging network, all of which influence both near-term growth and longer-term margin potential.
Refining Research with AI Tools
I often turn to Tickeron’s AI-powered tools when reviewing earnings reports like this one. The AI Screener helps quickly filter stocks by fundamentals, technical patterns, and performance metrics, which complements traditional earnings analysis and highlights comparable names in the healthcare space. It supports a more data-driven approach without replacing judgment on company-specific factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RDNT in upward trend: 10-day moving average broke above 50-day moving average on November 04, 2026
The 10-day moving average for RDNT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RDNT as a result. In 64 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for RDNT just turned positive on October 22, 2026. Looking at past instances where RDNT's MACD turned positive, the stock continued to rise in 47 of 55 cases over the following month. The odds of a continued upward trend are 85%.
RDNT moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDNT advanced for three days, in 230 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 181 of 210 cases where RDNT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for RDNT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 29 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
RDNT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.457) is normal, around the industry mean (67.298). RDNT's P/E Ratio (-292.308) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.567) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. RDNT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical imaging services
Industry MedicalSpecialties
Advertisement